# Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD

> **NCT03062540** · PHASE3 · TERMINATED · sponsor: **Tonix Pharmaceuticals, Inc.** · enrollment: 358 (actual)

## Conditions studied

- PTSD

## Interventions

- **DRUG:** TNX-102 SL
- **DRUG:** Placebo SL Tablet

## Key facts

- **NCT ID:** NCT03062540
- **Lead sponsor:** Tonix Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-03-27
- **Primary completion:** 2018-07-27
- **Final completion:** 2018-07-27
- **Target enrollment:** 358 (ACTUAL)
- **Why stopped:** Stopped early due to inadequate separation on primary efficacy endpoint at Week 12 according to Interim Analysis conducted on the first 274 (50%) patients.
- **Last updated:** 2024-05-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03062540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03062540, "Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT03062540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*